Jun 15–21, 2026 · 8 new studies, 3 reviews · Orthopaedic Oncology archive · All weeks
The new Orthopaedic Oncology research The Reduction sent the week of Jun 15–21, 2026, with the week’s most recent reviews, each with a one-line summary.
Get papers like these by email, free: subscribe to The Reduction, focused on your interests, on the days you pick.
Chordoma incidence is rising 1.47% annually in the US, varies by sex, race, and location, and distant-stage sacral tumors carry the worst survival at 38.3% at 5 years.
For primary osseous chest wall sarcomas, R0 resection is the strongest survival predictor, with 5-year OS of 85% for chondrosarcoma, 67% Ewing, and only 38% for osteosarcoma.
Lapatinib induces ferroptosis in osteosarcoma via the SLC1A5-GPX4 axis.
Lapatinib induces ferroptosis in osteosarcoma via the SLC1A5-GPX4 axis in lab and mouse models, providing preclinical rationale for drug repurposing.
Pediatric and young adult osteosarcoma survivors have high natural fertility rates comparable to the general population, reassuring patients and families during treatment counseling.
Comparative analysis of pelvic/sacral versus vertebral chordomas in the US from 2000 to 2020.
Vertebral chordoma location independently worsens survival on multivariate analysis despite similar unadjusted 5-year survival compared to pelvic/sacral chordomas, with surgery improving outcomes at both sites.
Distinguishing characteristics of carpal osteoid osteoma versus osteoblastoma: a comparative study.
Worsening night pain, NSAID relief, small lesion size, and high mineralization suggest carpal osteoid osteoma, while large lesion-to-carpal ratio favors osteoblastoma, aiding diagnosis without biopsy.
Unplanned soft tissue sarcoma excision independently worsened long-term survival and local recurrence, with differences emerging after 10 years, supporting extended surveillance.
The East Asian EAST-BMS machine-learning tool predicts postoperative survival in nonspinal bone metastasis surgery with better calibration than the Western SORG model for this population.
The Role of Denosumab in the Treatment of Primary Tumors of Bone.
Hand surgeons treating benign bone tumors should know denosumab can reduce pain, shrink tumor volume, and address lung metastases, even without an oncology referral.
Prophylactic antibiotics for massive endoprostheses in orthopaedic oncology.
The PARITY trial showed no benefit of extending antibiotic prophylaxis beyond 24 hours for tumor endoprostheses, though antibiotic choice questions remain, especially regarding cephalosporins.
Curettage with cancellous allograft achieves full range of motion in 81% of hand enchondromas; pathologic fracture, Ollier disease, and giant form lesions predict worse outcomes.
Home · All weeks · Archive · Subscribe · FAQ
© 2026 The Reduction